Assessment of Long-Term Efficacy and Tolerability of Nisoldipine by the Clinical Data Pool

Çağatay, Mustafa; Frost, Natasha A.; Weiß, Katja; Wiesner, K.

doi:10.1007/978-3-642-73010-8_29

Search citation statements

Order By: Relevance

Paper Sections

Select...

Nisoldipine1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1988

1989

Publication Types

Select...

Article2

Book2

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another chronic study on hypertension, nisoldipine (mean dose 32 mg daily) reduced systemic vascular resistance and blood pressure over 1 year; heart rate and cardiac index only rose after acute administration and there were no reports of dropouts due to headaches [67]. However, in a clinical data pool study, 22% of patients treated for hypertension with nisoldipine experienced headaches [68].…”

Section: Nisoldipinementioning

confidence: 99%

Calcium channel antagonists part V: Second-generation agents

Opie

1988

Cardiovasc Drug Ther

View full text Add to dashboard Cite

Second-generation agents include new dihydropyridines, such as amlodipine, felodipine, isradipine, nicardipine, nimodipine, nisoldipine, and nitrendipine. Verapamil-like agents include tiapamil, gallopamil, and anipamil. Among the diphenylalkylamines, bepridil is of special interest. New preparations of existing agents include slow-release formulations of nifedipine, verapamil, and diltiazem. From all these agents will be selected those that are longer-acting and provide higher vascular selectivity.

show abstract

Section: Nisoldipinementioning

confidence: 99%